On November 30, 2015 Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, reported the Company, in partnership with its collaborators, will present data from its product candidates and process development activities with six oral and poster presentations at the upcoming 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Juno, NOV 30, 2015, View Source;p=RssLanding&cat=news&id=2118842 [SID:1234508362]). Senior management will also review the data and provide an update on Juno’s ongoing clinical development strategy during an analyst and investor event and webcast.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first of two oral presentations will report updated data from the ongoing trial of JCAR014 in adults with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). This translational clinical research trial focuses on how optimization of the pharmacokinetics or exposure of JCAR014 relates to clinical outcomes. The second presentation will discuss the implications of prior allogeneic stem cell transplant and achievement of minimal residual disease negative complete remission in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) treated with JCAR015. Additionally, initial data from the anti-CD22 chimeric-antigen receptor (CAR) product candidate in pediatric and young adult relapsed or refractory ALL will be highlighted in one of four poster presentations.
"The clinical data in ALL, NHL, and CLL continue to be encouraging. The response rates and durability of responses across a range of B cell malignancies provide important insights on how persistence and depth of response translate into improved clinical outcomes, and are applicable to our portfolio broadly," said Hans Bishop, Juno’s President and Chief Executive Officer. "We are also looking forward to the first presentation of early results from the anti-CD22 CAR study in pediatric ALL patients, a study which appears to be of increasing relevance with the ongoing emergence, particularly in pediatric patients, of CD19 epitope loss with treatment."
The following data will be presented at ASH (Free ASH Whitepaper):
Oral Presentations
Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes (Abstract #184)
Presenter: Cameron J. Turtle, M.B.B.S., Ph.D., Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, and Department of Medicine, University of Washington, Seattle, WA
Date: Sunday, December 6, 2015: 8:15 a.m. Eastern Time
Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL (Abstract #682)
Presenter: Jae H. Park, M.D., Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Date: Monday, December 7, 2015: 3:30 p.m. Eastern Time
Poster Presentations
Clinical Activity and Persistence of Anti-CD22 Chimeric Antigen Receptor in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (Abstract #1324)
Presenter: Terry J. Fry, M.D., Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Date: Saturday, December 5, 2015: 5:30 p.m. – 7:30 p.m. Eastern Time
Functional Characterization of a T Cell Stimulation Reagent for the Production of Therapeutic Chimeric Antigen Receptor T Cells (Abstract #1901)
Presenter: Keenan T. Bashour, Ph.D., Department of Process & Analytical Development, Juno Therapeutics, Inc., Seattle, WA; Ryan P. Larson, Ph.D., Department of Translational Sciences, Juno Therapeutics, Inc., Seattle, WA
Date: Saturday, December 5, 2015: 5:30 p.m. – 7:30 p.m. Eastern Time
Multi-center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B Cell ALL (#2533)
Presenter: Kevin J. Curran, M.D., Department of Pediatrics and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
Date: Sunday, December 6, 2015: 6:00 p.m. – 8:00 p.m. Eastern Time
Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia (Abstract #3773)
Presenter: Cameron J. Turtle, M.B.B.S., Ph.D., Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, and Department of Medicine, University of Washington, Seattle, WA
Date: Monday, December 7, 2015: 6:00 p.m. – 8:00 p.m. Eastern Time
ASH Investor and Analyst Event and Webcast
The Juno ASH (Free ASH Whitepaper) Investor and Analyst Event and webcast will be held Monday, December 7, 2015, at 8:30 p.m. Eastern Time. The webcast can be accessed live on the Investor Relations page of Juno’s website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the event.